Molecule intelOpportunity: ModerateEssential

Erythromycin

93 brands · 69 companies · product forms

ATC: D10AF02, J01FA01, S01AA17 1 DRAP alert

Opportunity snapshot

Launch attractiveness
37
Market saturation
89
Price room
100
Regulatory risk
40
93
brands
69
companies
Rs 332.5
median price
33
price points
80.88x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 4%

Price room

Across observed sources and strengths
CheapestRs 42.83
MedianRs 332.5
Most expensiveRs 3,464
Spread80.88×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 80.88x across 33 trusted points (Rs 42.83-3464.0). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Erythromycin — each links to its own medicine page.

Regulatory alerts

latest 2022-11-29
Drug Safety Alert: Increased Risk of Cardiovascular Events with Co-administration and Inte

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(11) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

69 canonical companies and 93 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 80.88x across 33 trusted points (Rs 42.83-3464.0). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

1 DRAP alert(s), latest 2022-11-29.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.